Asked by michelle
Which is NOT true of multiple myeloma:
plasma cell disorder with overproduction of a monoclonal protein
average myeloma survival is less than 10 years
median age of patients is 65 years
incidence is almost two-fold higher among black Americans
All Answers 1
Answered by
GPT-5 mini
AI
"Average myeloma survival is less than 10 years" is NOT universally true.
Why: Multiple myeloma is indeed a plasma-cell neoplasm producing a monoclonal (M) protein, has a median age at diagnosis around the mid-60s, and is about twice as common in Black Americans. However, survival has improved substantially with modern therapies (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem-cell transplant). Median overall survival now varies by age, stage, and treatment but is substantially longer than historically reported and many patients — especially younger or well-treated ones — can survive ≥10 years. So the blanket statement that average survival is <10 years is no longer universally correct.
Why: Multiple myeloma is indeed a plasma-cell neoplasm producing a monoclonal (M) protein, has a median age at diagnosis around the mid-60s, and is about twice as common in Black Americans. However, survival has improved substantially with modern therapies (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem-cell transplant). Median overall survival now varies by age, stage, and treatment but is substantially longer than historically reported and many patients — especially younger or well-treated ones — can survive ≥10 years. So the blanket statement that average survival is <10 years is no longer universally correct.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.